Mankind Pharma has announced a board meeting scheduled for February 3, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025 (Q3 FY26). The trading window for the company’s securities will remain closed until February 5, 2026.
Board Meeting Announcement
Mankind Pharma has scheduled a meeting of its Board of Directors to be held on February 3, 2026. The primary agenda is to consider and approve the unaudited financial results for the third quarter (Q3) and nine months ending December 31, 2025.
Financial Results Focus
The board will specifically review the standalone and consolidated financial performance of the company. This will provide investors with insights into Mankind Pharma’s operational and financial standing for Q3 FY26.
Trading Window Closure
As previously announced on December 24, 2025, the trading window for the company’s securities remains closed. It will remain closed until February 5, 2026. This is in accordance with regulations regarding the prevention of insider trading.
Source: BSE
